Last updated: October 23, 2026
Metacresol, also called m-cresol or 3-methylphenol, is a specialty preservative used mainly in multidose insulin and injectable biologic formulations. Its pharmaceutical market is small compared with the broader cresols and industrial chemicals markets, but it has high formulation relevance because manufacturers must maintain antimicrobial protection without damaging protein stability.
The market has four defining characteristics:
- Demand is linked to injectable biologic production, especially multidose insulin.
- Revenue is driven more by qualification, purity, and supply continuity than by raw-material volume.
- The molecule has no meaningful standalone patent exclusivity.
- Financial growth is likely to track insulin and injectable biologic volumes, while unit-price expansion remains limited by chemical substitutability and multiple industrial suppliers.
No authoritative public market series isolates pharmaceutical-grade metacresol revenue from industrial m-cresol, cresylic acids, or other preservative markets. Financial analysis therefore depends on end-use demand, supplier economics, regulatory qualification, and public drug-product volumes.
What is metacresol and how is it used in pharmaceuticals?
Metacresol is an aromatic phenol with the chemical name 3-methylphenol and CAS Registry Number 108-39-4. It is used as an antimicrobial preservative and formulation excipient in injectable products.
| Attribute |
Metacresol |
| Chemical name |
3-Methylphenol |
| Common names |
m-Cresol, metacresol |
| CAS number |
108-39-4 |
| Formula |
C7H8O |
| Primary pharmaceutical role |
Antimicrobial preservative |
| Main dosage forms |
Multidose injectable solutions and suspensions |
| Principal demand segment |
Insulin and other protein therapeutics |
| Patent status |
No meaningful composition-of-matter exclusivity |
| Regulatory role |
Inactive ingredient or formulation excipient, depending on product classification |
Metacresol is particularly valuable in multidose injection systems because the formulation may be repeatedly accessed over the product’s in-use period. The preservative helps control microbial growth after vial or cartridge puncture. Its concentration is product-specific and depends on formulation pH, protein concentration, container closure, compatibility, and required in-use stability.
Public FDA labeling confirms its use in several major insulin products. Humalog insulin lispro contains 3.15 mg/mL of m-cresol. Lantus insulin glargine contains 2.7 mg/mL of m-cresol. NovoLog insulin aspart contains 1.72 mg/mL of m-cresol and 1.50 mg/mL of phenol. These products are manufactured by Eli Lilly, Sanofi, and Novo Nordisk, respectively. [1-3]
Which pharmaceutical products use metacresol?
Metacresol is most closely associated with insulin, although the excipient can be used in other injectable biologics where preservative protection is required.
Major insulin products containing metacresol
| Product |
Active ingredient |
Manufacturer |
Reported metacresol concentration |
| Humalog |
Insulin lispro |
Eli Lilly |
3.15 mg/mL |
| Lantus |
Insulin glargine |
Sanofi |
2.7 mg/mL |
| NovoLog |
Insulin aspart |
Novo Nordisk |
1.72 mg/mL |
| Tresiba |
Insulin degludec |
Novo Nordisk |
Product-specific; label identifies metacresol among excipients |
| Humulin products |
Human insulin |
Eli Lilly |
Product-specific |
Concentrations differ by presentation. A 10 mL multidose vial can contain tens of milligrams of metacresol, while a 3 mL cartridge uses proportionally less. The excipient’s value is therefore tied to the number of filled units and the share of products sold in multidose formats, rather than the amount used per individual dose.
Metacresol is not interchangeable across products without formulation work. A change to phenol, benzyl alcohol, chlorobutanol, or a preservative-free design can affect protein aggregation, adsorption, injection tolerability, container compatibility, and shelf life.
How large is the metacresol pharmaceutical market?
The pharmaceutical-grade metacresol market is a niche subsegment of the global cresols and specialty phenols market. Public chemical-industry reports generally aggregate m-cresol with p-cresol, o-cresol, cresylic acids, or mixed cresol streams. They do not reliably separate revenue from pharmaceutical excipient sales.
A practical market model is:
Pharmaceutical metacresol revenue = qualifying product volume × average pharmaceutical-grade price
The product volume is relatively modest because metacresol is used at low concentrations. The value density is higher than bulk industrial m-cresol because pharmaceutical customers require:
- Controlled impurity profiles
- Batch-to-batch consistency
- Validated analytical methods
- Traceability
- Change-control documentation
- Regulatory support
- Long-term supply continuity
- Packaging suitable for pharmaceutical manufacturing
The commercial market is likely concentrated among a limited number of qualified producers and distributors. Industrial-grade supply cannot automatically substitute for pharmaceutical-grade material. A drug manufacturer must qualify the specific source, manufacturing site, specifications, test methods, and change history.
What drives demand for pharmaceutical-grade metacresol?
Insulin volume growth
Insulin is the primary demand anchor. Global diabetes prevalence, insulin-treated patient numbers, and production growth support baseline metacresol demand. The International Diabetes Federation estimated that 537 million adults aged 20 to 79 were living with diabetes in 2021 and projected 783 million by 2045. [4]
Demand does not rise one-for-one with patient growth. It depends on:
- Use of insulin versus non-insulin therapies
- Daily dose levels
- Vial, cartridge, and pen formats
- Multidose versus single-use packaging
- Geographic access to insulin
- Biosimilar and follow-on insulin penetration
- Manufacturer-specific formulation choices
The growth of prefilled pens and cartridges can increase the number of packaged units while reducing the metacresol quantity per container compared with large multidose vials.
Expansion of injectable biologics
Metacresol can benefit from broader growth in protein therapeutics and injectable biologics. Its use is technically constrained, however. Many biologics are supplied as single-dose products, lyophilized powders, or preservative-free formulations. Others use alternative preservatives or rely on aseptic single-use packaging.
Follow-on and biosimilar insulin
Biosimilar insulin products may use metacresol when the reference formulation, delivery device, and multidose-use requirements make it technically appropriate. This can expand excipient demand even when branded insulin loses market share.
The commercial effect is mixed. More suppliers of insulin can increase total filled volume, but procurement teams may seek lower-cost alternatives, dual sourcing, or different preservative systems.
Manufacturing localization
The expansion of pharmaceutical manufacturing in China, India, the Middle East, and other emerging production centers can increase demand for qualified local or regional excipient supply. Qualification cycles remain lengthy because changes to an established injectable formulation can require stability, compatibility, and regulatory documentation.
What are the main constraints on metacresol market growth?
The largest constraints are technical substitution, low use concentration, and the absence of a proprietary product moat.
Preservative-free presentations can reduce demand. Single-dose vials, prefilled syringes, autoinjectors, and sealed cartridge systems reduce repeated access and may eliminate the need for a preservative. Regulatory and patient-safety preferences can favor these formats in selected products.
Metacresol also faces competition from phenol and other antimicrobial systems. NovoLog, for example, uses both m-cresol and phenol. [3] The choice is formulation-specific, so a supplier cannot assume that growth in injectable biologics will translate directly into metacresol growth.
Protein compatibility is another barrier. Preservatives can interact with proteins, surfactants, elastomers, and container surfaces. A change in preservative concentration may alter aggregation, potency, particulate formation, or injection-site tolerability.
How strong is the patent estate for metacresol?
Metacresol has no meaningful standalone patent estate protecting the molecule as a pharmaceutical excipient. The compound is a long-established chemical and is available from multiple chemical suppliers.
| IP category |
Metacresol position |
| Composition-of-matter patent |
No commercially relevant exclusivity |
| Pharmaceutical excipient patent |
No broad standalone exclusivity identified |
| Formulation patents |
Possible at the finished-product level |
| Method-of-use patents |
Possible for particular biologic formulations or delivery systems |
| Manufacturing patents |
Possible for purification or process control |
| Orange Book listing |
No standalone metacresol listing |
| Paragraph IV exposure |
Applies to an abbreviated drug application challenging listed drug patents, not to metacresol itself |
The relevant intellectual-property risk is at the drug-product level. Insulin manufacturers may have patents covering formulations, concentrations, delivery devices, container systems, manufacturing processes, or therapeutic uses. Those rights can affect generic or follow-on entry without creating exclusivity around metacresol.
What is the FDA regulatory status of metacresol?
Metacresol is used as an excipient in approved injectable drug products, but it is not an independently approved active pharmaceutical ingredient for treating disease.
The FDA evaluates excipients in the context of a finished drug application. The agency reviews identity, purity, manufacturing controls, toxicology, compatibility, concentration, stability, and exposure through the drug product. FDA labeling identifies inactive ingredients for approved products, including insulin formulations that contain m-cresol. [1-3]
The Inactive Ingredient Database can support regulatory precedent, but database presence does not create a blanket approval for every route, concentration, dosage form, or patient population. A manufacturer changing the source or specification may need comparability and quality documentation, especially for a sensitive biologic.
Relevant quality frameworks include:
- USP-NF monograph and general quality requirements, where applicable
- European Pharmacopoeia requirements, where applicable
- ICH Q7 principles for active and excipient-related manufacturing controls
- ICH Q9 quality-risk management
- ICH Q10 pharmaceutical quality systems
- FDA current good manufacturing practice requirements
Which companies supply or compete in the metacresol market?
The supply chain includes chemical producers, pharmaceutical-grade excipient manufacturers, and specialty distributors. Public disclosure of supplier relationships for branded insulin products is limited. Drug manufacturers generally do not identify all excipient vendors in product labeling.
Competition occurs on five variables:
- Pharmaceutical purity and impurity control.
- Regulatory documentation and audit readiness.
- Supply continuity and geographic redundancy.
- Batch size and delivery reliability.
- Price relative to qualified alternatives.
The upstream market is exposed to phenol, toluene, and other petrochemical feedstocks. Production economics can therefore be affected by crude-oil-linked costs, refinery operations, regional chemical capacity, energy prices, and freight.
A supplier with a qualified source can retain business despite higher pricing because changing excipient suppliers creates regulatory and manufacturing risk. This produces moderate switching costs even though the underlying molecule is not proprietary.
What licensing deals and litigation affect metacresol?
No major publicly disclosed licensing transaction is centered on metacresol as an excipient. Commercial agreements are more likely to involve insulin products, delivery devices, contract manufacturing, or broader excipient supply arrangements.
Likewise, litigation is generally directed at insulin formulation patents, biosimilar applications, delivery systems, or manufacturing processes rather than at metacresol itself. A Paragraph IV certification could challenge patents covering a finished insulin product, but it would not challenge ownership of the metacresol molecule.
The principal legal risks are therefore indirect:
- A formulation patent may restrict a generic or biosimilar product using metacresol.
- A supplier-change process may trigger regulatory documentation requirements.
- A manufacturing patent may cover a purification or formulation process.
- A supply agreement may create concentration or termination risk.
- A product-liability dispute may examine preservative concentration or tolerability.
What is the financial trajectory for metacresol?
The likely financial trajectory is steady, specialized growth rather than rapid expansion. Revenue should be supported by insulin demand and injectable biologics, but constrained by low dosage concentration, mature chemistry, and preservative-free product development.
| Financial variable |
Expected direction |
Rationale |
| Volume demand |
Low-to-moderate growth |
Insulin and injectable biologic production growth |
| Average selling price |
Stable to modestly increasing |
Qualification value offsets commodity competition |
| Gross margin |
Above industrial m-cresol, below proprietary excipients |
Pharmaceutical documentation adds value, but molecule is nonexclusive |
| Customer concentration |
High |
Major insulin manufacturers account for substantial demand |
| Capital intensity |
Moderate |
Requires quality systems, analytical control, and validated production |
| Switching costs |
Moderate to high |
Source changes can require qualification and comparability work |
| Patent protection |
Minimal |
No molecule-level exclusivity |
| Supply risk |
Moderate |
Limited qualified sources and petrochemical feedstock exposure |
| Long-term substitution risk |
Moderate |
Single-dose systems and preservative-free formulations |
The best financial position belongs to suppliers with approved or qualified pharmaceutical-grade material, multiple production regions, and established relationships with insulin and biologics manufacturers. Commodity producers without pharmaceutical documentation are more exposed to price competition.
How does metacresol compare with phenol as an injectable preservative?
| Factor |
Metacresol |
Phenol |
| Main use |
Insulin and injectable biologics |
Insulin and injectable biologics |
| Technical role |
Antimicrobial preservative |
Antimicrobial preservative |
| Product use |
Often used alone or with phenol |
Often used alone or with metacresol |
| Regulatory precedent |
Established in approved insulin products |
Established in approved insulin products |
| Patent position |
No meaningful molecule-level exclusivity |
No meaningful molecule-level exclusivity |
| Substitution |
Formulation-specific |
Formulation-specific |
| Commercial risk |
Source qualification and supply continuity |
Same, with different impurity and compatibility profiles |
Neither compound is a universal replacement for the other. Finished-product performance determines the choice. A manufacturer must assess antimicrobial effectiveness, protein stability, container compatibility, toxicology, and patient exposure before changing the preservative system.
What generic entry risks exist for metacresol-containing insulin?
Generic and biosimilar entry does not create a direct metacresol patent cliff. The main risks concern the finished insulin product.
Potential entry pathways include:
- Abbreviated new drug applications for eligible insulin products
- Biologics license applications and biosimilar applications
- Follow-on insulin products with different device presentations
- Authorized generics or branded-generic arrangements
- Regional products using similar preservative systems
An entrant using metacresol may reduce technical development risk if the preservative has established precedent in the reference product. It still must demonstrate product quality, stability, delivery-device compatibility, and applicable interchangeability or substitutability requirements.
What is the geographic outlook?
North America and Europe remain important because of established insulin manufacturing and high regulatory standards. Asia-Pacific is the strongest long-term volume opportunity because of insulin demand, biopharmaceutical investment, and regional manufacturing expansion.
| Region |
Market outlook |
| United States |
Stable demand, high qualification standards, strong shift toward pens and devices |
| Europe |
Stable insulin base, strict excipient and supply-chain controls |
| China |
Expanding biologics and insulin manufacturing, increasing local sourcing |
| India |
Growing insulin and injectable manufacturing base |
| Latin America |
Demand tied to diabetes prevalence and access expansion |
| Middle East and Africa |
Long-term growth constrained by affordability and supply infrastructure |
Key Takeaways
- Metacresol is a specialized preservative excipient used primarily in multidose insulin and selected injectable biologics.
- Its pharmaceutical market is not separately reported with reliable public revenue data.
- Demand is linked to insulin production, multidose packaging, and biologic manufacturing.
- The molecule has no meaningful standalone patent exclusivity and no independent Orange Book position.
- Finished-product formulation patents, device patents, and insulin litigation remain the relevant legal constraints.
- Pharmaceutical-grade supply commands a premium because of qualification, documentation, and continuity requirements.
- Preservative-free products, single-dose systems, and alternative preservatives are the main long-term demand risks.
- Financial growth should be moderate, with stronger prospects for qualified suppliers than for undifferentiated chemical producers.
FAQs
Is metacresol the same as m-cresol?
Yes. Metacresol and m-cresol are common names for 3-methylphenol, a phenolic compound identified by CAS 108-39-4.
Does metacresol have a patent expiration date?
There is no commercially relevant molecule-level patent expiration date because metacresol is an established chemical with no meaningful standalone pharmaceutical exclusivity.
Is metacresol listed in the Orange Book?
Metacresol itself is not an Orange Book-listed drug. Orange Book listings apply to approved finished drug products and their relevant patents or exclusivity, not to ordinary excipients as standalone products.
Can phenol replace metacresol in an insulin formulation?
Not automatically. The manufacturer must establish antimicrobial performance, protein stability, compatibility, safety, and regulatory acceptability for the specific formulation.
Which pharmaceutical companies create the most demand for metacresol?
Eli Lilly, Novo Nordisk, and Sanofi are major sources of demand because their insulin portfolios include products labeled with metacresol or m-cresol. Demand from other injectable biologic manufacturers is product-specific and less transparent.
References
-
U.S. Food and Drug Administration. (2023). Humalog insulin lispro injection prescribing information. Eli Lilly and Company.
-
U.S. Food and Drug Administration. (2023). Lantus insulin glargine injection prescribing information. Sanofi-Aventis U.S. LLC.
-
U.S. Food and Drug Administration. (2023). NovoLog insulin aspart injection prescribing information. Novo Nordisk A/S.
-
International Diabetes Federation. (2021). IDF diabetes atlas (10th ed.). International Diabetes Federation.
-
U.S. Food and Drug Administration. (2024). Inactive ingredient database. U.S. Department of Health and Human Services.
-
United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP Convention.
